Hologic, Inc.'s (HOLX) robust strength in the molecular diagnostics business places it well for growth in the upcoming quarters. The company's Breast Health franchise is now more diverse with the newest acquisition. Sound financial stability also bodes well. Meanwhile, the impact of macroeconomic conditions and adverse currency fluctuations remain a concern for Hologic's operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 8.2% compared with the 11.8% growth of the industry and a 26.3% ...